Experiment Overview
| Repository ID: | FR-FCM-Z2JH | Experiment name: | Mass cytometry on PBMCs from patients with chronic lympocytic leukaemia (CLL) | MIFlowCyt score: | 31.50% |
| Primary researcher: | Tamara Davenne | PI/manager: | Jan Rehwinkel | Uploaded by: | Tamara Davenne |
| Experiment dates: | 2018-03-01 - 2018-03-30 | Dataset uploaded: | Apr 2020 | Last updated: | Apr 2020 |
| Keywords: | [CLL] [APOPTOSIS] [CyTOF; mass cytometry; flow cytometry; standardization] [SAMHD1] [forodesine] [deoxyguanosine] | Manuscripts: | |||
| Organizations: |
MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Radcliffe Department of Medicine, Oxford, (UK)
|
||||
| Purpose: | Quantify apoptosis by mass cytometry in CLL PBMCs treated with forodesine + deoxyguanosine. Samples were divided into two groups: with SAMHD1 mutations and without SAMHD1 mutation. No SAMHD1 protein was detected in SAMHD1 mutated group, confirming loss-of-function mutation. | ||||
| Conclusion: | Only leukaemic cells that did not express SAMHD1 (harbouring SAMHD1 mutation) showed increased levels of cleaved-PARP and cleaved-CASPASE3. | ||||
| Comments: | The leukaemic population in PBMCs could be divided into active and inactive cells. Active cells are characterised by active MAPK, NF-kb and JAK/STAT signalling pathways, as shown by the phosphorylated proteins of that pathway identified by mass cytometry. File names correspond to patient ID referred to in our manuscript https://www.biorxiv.org/content/10.1101/2020.02.17.951517v1.full . H1, H2 and H3 are healthy donors. | ||||
| Funding: | This work was funded by the UK Medical Research Council [MRC core funding of the MRC Human Immunology Unit; J.R.]; the Wellcome Trust [grant number 100954; J.R]. T.D. was supported by the Wellcome Trust Infection, Immunology & Translational Medicine doctoral programme [grant number 105400/Z/14/Z] | ||||
| Quality control: | Samples were concatenated and debarcoded | ||||
